NASDAQ:XFOR X4 Pharmaceuticals Q2 2026 Earnings Results & Report $2.59 -0.05 (-1.89%) Closing price 04:00 PM EasternExtended Trading$2.59 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. X4 Pharmaceuticals beat analyst expectations on both earnings and revenue in its Q2 2026 results, released August 6, 2026. The company reported EPS of -$0.13 versus the -$0.1760 consensus estimate, while revenue of $8.81 million topped the $2.42 million estimate by $6.39 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 6, 2026TimeAfter Market ClosesConference Call7:00 AM ET X4 Pharmaceuticals EPS ResultsActual EPS-$0.13Consensus EPS -$0.1760Beat/MissBeat by +$0.0460One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersX4 Pharmaceuticals Revenue ResultsActual Revenue$8.81 millionExpected Revenue$2.42 millionBeat/MissBeat by +$6.39 millionYoY Revenue GrowthN/AUpcoming EarningsX4 Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 9, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) X4 Pharmaceuticals Q2 2026 Earnings FAQ Did X4 Pharmaceuticals beat earnings estimates for Q2 2026? X4 Pharmaceuticals (NASDAQ:XFOR) reported earnings of -$0.13 per share for Q2 2026, beating the consensus estimate of -$0.1760. The report was announced on Thursday, August 6, 2026. What was X4 Pharmaceuticals' revenue for Q2 2026? X4 Pharmaceuticals reported revenue of $8.81 million for Q2 2026, against a consensus estimate of $2.42 million. When is X4 Pharmaceuticals' next earnings date? X4 Pharmaceuticals' next earnings date is estimated for Wednesday, November 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for X4 Pharmaceuticals on the company's earnings history page. X4 Pharmaceuticals Earnings HeadlinesX4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion LeadersOctober 9, 2026 | globenewswire.comX4 Pharmaceuticals Enters Up to $150 Million Term Loan FacilityOctober 8, 2026 | marketscreener.comMA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the eye-popping yields are fueling a boom among everyday investors. Three years ago, barely a dozen of these funds existed - today there are more than 100, holding over $140 billion. These funds trade on the NYSE and NASDAQ and are built to generate monthly income. Some investors are targeting $5,000 a month with roughly one-tenth of the nest egg Wall Street says you need.October 16 at 1:00 AM | Investors Alley (Ad)X4 Strengthens Cash Position Ahead Of Key Phase 3 MilestonesOctober 8, 2026 | rttnews.comX4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVenturesOctober 8, 2026 | finance.yahoo.comX4 Pharmaceuticals secures up to $150M debt facilityOctober 8, 2026 | msn.comSee More X4 Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like X4 Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on X4 Pharmaceuticals and other key companies, straight to your email. Email Address About X4 PharmaceuticalsX4 Pharmaceuticals (NASDAQ:XFOR) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases caused by immune and hematologic dysfunction. The company’s research centers on the CXCR4 biological pathway, which regulates the movement and retention of certain immune cells in the bone marrow and other tissues. X4’s primary product is XOLREMDI (mavorixafor), an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration in 2024 for use in people aged 12 and older with WHIM syndrome. WHIM syndrome is a rare, inherited immunodeficiency that can cause chronic neutropenia, lymphopenia and recurrent infections. XOLREMDI is designed to increase the number of circulating neutrophils and lymphocytes, potentially helping reduce infection-related complications. Founded in 2014 and headquartered in Boston, Massachusetts, X4 Pharmaceuticals has historically focused on rare immunological and hematological disorders with significant unmet medical needs. In addition to its commercial efforts for XOLREMDI in the United States, the company has evaluated mavorixafor in other forms of chronic neutropenia and related conditions. X4 Pharmaceuticals trades on the Nasdaq under the symbol XFOR.View X4 Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Bank of America Stock Sell-Off Looks Like a Buying OpportunityMorgan Stanley Beats on Earnings, But Shares Fall on Trading MixFundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?Palantir's Potential Next Catalyst After Retail Profit-TakingApple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
